February 13, 2026

Using AI to Retrace the Evolution of Genetic Control Elements in the Brain

Using AI to Retrace the Evolution of Genetic Control Elements in the Brain

Researchers map evolutionary changes in the developing mammalian cerebellum

Artificial intelligence allows tracing the evolution of genetic control elements in the developing mammalian cerebellum. An international research team led by biologists from Heidelberg University as well as the Vlaams Instituut voor Biotechnologie and KU Leuven (Belgium) has now developed advanced AI models that can predict the activity of these elements based solely on their DNA sequence. Using these models, the scientists were able to retrace the evolutionary changes in the control programs, also identifying those that are specific to the human lineage.

Genetic control elements are DNA sequences that determine where and when genes are switched on. Changes in the activity of these elements can drive evolutionary innovations – such as the expansion of the brain. One brain region that notably expanded during human evolution is the cerebellum, which, beyond its role in movement and balance, also contributes to cognition, emotion, and language. “Tracing the evolution of genetic control elements has long been challenging due to their rapid evolutionary turnover and our limited understanding of how their activity is encoded in their DNA sequence,” explains Prof. Dr Henrik Kaessmann, a research group leader at the Center for Molecular Biology of Heidelberg University (ZMBH).

To close this knowledge gap, the researchers made use of advances in artificial intelligence. “Customized tools for the AI-based analysis of comprehensive and complex datasets in the life sciences have allowed us to decode the sequence grammar and hence the genetically coded activity profiles of these control elements,” states Prof. Dr Stein Aerts, a computational biologist at the Vlaams Instituut voor Biotechnologie and KU Leuven who co-led the research studies with Prof. Kaessmann.

The researchers used modern sequencing technologies to map the activity of these elements in individual cells in the developing cerebellum of human, bonobo, macaque, marmoset, mouse, and opossum. Using this unique dataset, they trained models based on machine learning in order to be able to predict control element activity directly from the respective DNA sequence. These AI models were not only able to model the activity of these elements in the six species studied, but also to accurately predict the activity across other mammals. “This goes to show that the sequence rules that define genetic control elements in cerebellar cell types have been highly conserved throughout mammalian evolution,” explains Dr Ioannis Sarropoulos, formerly a doctoral student in Prof. Kaessmann’s group and co-first author of a paper that has been published on the latest research findings – alongside Dr Mari Sepp, a former Kaessmann lab postdoc, and doctoral candidate Tetsuya Yamada.

Building on these findings, the scientists leveraged the AI models’ ability to recognize conserved sequence rules to predict the activity of control elements in 240 mammalian species. For every human element, the researchers succeeded in identifying whether the corresponding sequence is active in other mammals. This allowed them to reconstruct the evolutionary history of human regulatory programs at high resolution and identify those that likely contributed to key evolutionary innovations in the human cerebellum. For example, they discovered a new control element near the gene THRB, which encodes a thyroid hormone receptor found in all vertebrates. This new element has enabled this gene to also operate in cerebellar stem cells. According to Prof. Kaessmann, this could have contributed to the evolutionary expansion of the human cerebellum. “That an evolutionarily ancient gene can be repurposed for novel functions is a key mechanism by which evolution drives innovation,” emphasizes the Heidelberg molecular biologist.

In addition to the teams from Heidelberg and Leuven, researchers from Göttingen and Leipzig as well as Hungary and the United Kingdom contributed to the study. The project was funded by various organizations and foundations, including the European Research Council, the European Molecular Biology Organization, and the Simons Foundation. The results of the study were published in the journal “Science”.

Original publication

I. Sarropoulos, M. Sepp, T. Yamada, P.S.L. Schäfer, N. Trost, J. Schmidt, C. Schneider, C. Drummer, S. Mißbach, I.I. Taskiran, N. Hecker, C. Bravo González-Blas, R. Frömel, P. Joshi, E. Leushkin, F. Arnskötter, K. Leiss, K. Okonechnikov, S. Lisgo, M. Palkovits, S. Pääbo, M. Cardoso-Moreira, L.M. Kutscher, R. Behr, S.M. Pfister, S. Aerts, and H. Kaessmann: The evolution of gene regulation in mammalian cerebellum development. Science (published online 29 January 2026).

Further information

Our latest News

discover more
Tailor-Made Fertilization

Tailor-Made Fertilization

Excessive fertilization in agriculture weakens crops, threatens drinking water quality, and harms the soil. Researchers at the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB are now developing an alternative fertilizer that is fully biodegradable, supplies plants exclusively with the nutrients they need, and prevents over-fertilization. More information in German below: Jahr für Jahr werden […]

Two German Cancer Awards for Researchers at Heidelberg University’s Faculty of Medicine

Two German Cancer Awards for Researchers at Heidelberg University’s Faculty of Medicine

Professor Dr. Jessica Hassel, Faculty of Medicine Heidelberg at Heidelberg University and Head of the Skin Cancer Center at Heidelberg University Hospital and the National Center for Tumor Diseases (NCT) Heidelberg, has been awarded in the category “Clinical Research.” Professor Dr. Dr. Felix Sahm, also from the Faculty of Medicine Heidelberg, Department of Neuropathology at […]

Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease

Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease

Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease Paris, March 31, 2026. The European Commission has granted a conditional marketing authorisation for Rezurock (belumosudil) for the treatment of chronic graft-versus-host disease (GVHD) in adults and in children aged 12 years and older with a body weight of at least 40 kg. The medicine is to […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp